101 related articles for article (PubMed ID: 20925220)
1. Impact of personalized medicine on diagnostics and therapeutics.
Sitaraman R
Natl Med J India; 2010; 23(2):124. PubMed ID: 20925220
[No Abstract] [Full Text] [Related]
2. Personalized medicine: a paradigm for a sustainable pharmaceutical industry?
Chackalamannil S; Desai MC
Curr Opin Drug Discov Devel; 2009 Jul; 12(4):443-5. PubMed ID: 19562640
[TBL] [Abstract][Full Text] [Related]
3. Personalized medicine: changing the paradigm of drug development.
Couch RD; Mott BT
Methods Mol Biol; 2012; 823():367-78. PubMed ID: 22081358
[TBL] [Abstract][Full Text] [Related]
4. Personalized medicine: potential impact on the biopharmaceutical industry.
Malik NN; Khan Y
Drug Discov Today; 2010 Nov; 15(21-22):881-3. PubMed ID: 20833263
[No Abstract] [Full Text] [Related]
5. Regulation and the fate of personalized medicine.
Greenbaum D
Virtual Mentor; 2012 Aug; 14(8):645-52. PubMed ID: 23351321
[No Abstract] [Full Text] [Related]
6. Nanobiotechnology and personalized medicine.
Jain KK
Prog Mol Biol Transl Sci; 2011; 104():325-54. PubMed ID: 22093223
[TBL] [Abstract][Full Text] [Related]
7. Progress towards personalized medicine.
Bates S
Drug Discov Today; 2010 Feb; 15(3-4):115-20. PubMed ID: 19914397
[TBL] [Abstract][Full Text] [Related]
8. The impact of genetic biomarkers on drug and companion diagnostic return on investment.
Keeling P
Drug Discov Today; 2011 Oct; 16(19-20):850-1. PubMed ID: 21906694
[No Abstract] [Full Text] [Related]
9. Challenges of drug discovery for personalized medicine.
Jain KK
Curr Opin Mol Ther; 2006 Dec; 8(6):487-92. PubMed ID: 17243483
[TBL] [Abstract][Full Text] [Related]
10. [Personalized medicine--genomic phase].
Brdicka R
Cas Lek Cesk; 2009; 148(10):477-80. PubMed ID: 20662409
[TBL] [Abstract][Full Text] [Related]
11. Market watch: industry perspectives on personalized medicine.
Zuckerman R; Milne CP
Nat Rev Drug Discov; 2012 Mar; 11(3):178. PubMed ID: 22378258
[No Abstract] [Full Text] [Related]
12. Overcoming the obstacles in the pharma/biotech industry: 2009 update.
Graul AI; Revel L; Tell M; Rosa E; Cruces E
Drug News Perspect; 2010; 23(1):48-63. PubMed ID: 20155219
[TBL] [Abstract][Full Text] [Related]
13. Companion diagnostics: an emerging component in personalized medicine.
Patterson B
MLO Med Lab Obs; 2014 Feb; 46(2):10-1. PubMed ID: 24672846
[No Abstract] [Full Text] [Related]
14. Financial Times Global Pharmaceutical & Biotechnology Conference 2009.
Scattereggia J
IDrugs; 2010 Jan; 13(1):26-9. PubMed ID: 20024844
[TBL] [Abstract][Full Text] [Related]
15. R&D policy, agency costs and innovation in personalized medicine.
Yin W
J Health Econ; 2009 Sep; 28(5):950-62. PubMed ID: 19671480
[TBL] [Abstract][Full Text] [Related]
16. Personalized medicine: elusive dream or imminent reality?
Lesko LJ
Clin Pharmacol Ther; 2007 Jun; 81(6):807-16. PubMed ID: 17505496
[TBL] [Abstract][Full Text] [Related]
17. Redefining personalized medicine in the postgenomic era: developing bladder cancer therapeutics with proteomics.
Blanchet KD
BJU Int; 2010 Jan; 105(2):i-iii. PubMed ID: 20078597
[No Abstract] [Full Text] [Related]
18. Legal developments and practical implications of gene patenting on targeted drug discovery and development.
Klein RD
Clin Pharmacol Ther; 2010 Jun; 87(6):633-5. PubMed ID: 20485317
[TBL] [Abstract][Full Text] [Related]
19. Insurers skeptical of usefulness of companion diagnostics.
Manag Care; 2012 Apr; 21(4):49. PubMed ID: 22593857
[No Abstract] [Full Text] [Related]
20. The integration of molecular diagnostics with therapeutics. Implications for drug development and pathology practice.
Ross JS; Ginsburg GS
Am J Clin Pathol; 2003 Jan; 119(1):26-36. PubMed ID: 12520694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
